Top 50 Life Science Startup Investors in United States in September 2025
A list of 50 angel investors and VC (Venture Capital) funds that invest in Life science startups based in United states. We rank investors based on the number of investments they made in Life science companies from United states. We update this investor list every month.Top 50 Life Science Startup Investors in United States in September 2025
Investor | Life Science United States investments |
---|---|
ARCH Venture Partners | 24 |
SOSV | 21 |
Alexandria Venture Investments | 20 |
Northpond Ventures | 19 |
RA Capital Management | 15 |
Novartis Venture Fund | 14 |
Third Rock Ventures | 13 |
Atlas Venture | 13 |
DCVC | 13 |
8VC | 12 |
Alix Ventures | 12 |
Civilization Ventures | 12 |
OrbiMed | 12 |
Andreessen Horowitz | 11 |
Fifty Years | 11 |
Hatteras Venture Partners | 11 |
KdT Ventures | 10 |
MPM Capital | 10 |
Sahsen Ventures | 10 |
Artis Ventures | 10 |
Rev1 Ventures | 9 |
Flagship Pioneering | 9 |
GV | 9 |
Longwood Fund | 9 |
Cormorant Asset Management | 8 |
Playground Global | 8 |
Apple Tree Partners | 8 |
iSelect Fund | 8 |
New Enterprise Associates | 8 |
Pear VC | 8 |
The Column Group | 8 |
Vivo Capital | 8 |
SR One | 8 |
Lux Capital | 8 |
Versant Ventures | 8 |
5AM Ventures | 8 |
Omega Funds | 7 |
Breakout Ventures | 7 |
Oreilly AlphaTech Ventures | 7 |
Mission BioCapital | 7 |
Dolby Family Ventures | 7 |
Digitalis Ventures | 7 |
Connecticut Innovations | 7 |
Horizons Ventures | 7 |
Foresite Capital | 7 |
Illumina Ventures | 7 |
F-Prime Capital | 6 |
Roche Venture Fund | 6 |
JDRF T1D Fund | 6 |
First Round Capital | 6 |
ARCH Venture Partners provides seed / early stage venture capital for technology firms in information technology, life sciences, and physical sciences
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, China, United Kingdom
Portfolio highlights
- Dispatch Bio — Dispatch Bio helps create a world where all cancer patients can be cured.
- Atlas Data Storage — Atlas Data Storage develops data storage systems utilizing synthetic DNA to encode digital information. The company offers end-to-end solutions that integrate semiconductor-based synthesis and enzyme engineering to store data in DNA strands. This approach aims to provide long-term, high-density storage options for various sectors. Atlas DataStorage's technology is designed to address the growing demand for scalable and energy-efficient data storage solutions.
- Kriya Therapeutics — Kriya is a biopharmaceutical company developing gene therapy to address common diseases that impact millions of people worldwide. Learn more.
SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates.
HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.
Show more
Investment focus
- Biotechnology, Health Care, Software
- Seed, Convertible Note, Pre-Seed
- United States, India, United Kingdom
Portfolio highlights
- MixRift — MIXRIFT - game developers specialized in Mixed Reality
- unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
- Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.
Alexandria Venture Investments is a venture capital firm that develops work in real estate technology, and healthcare sectors. The company's strategic venture capital platform is Alexandria Venture Investments. Since its inception in 1996, the company has invested in disruptive life science, agrifood tech, and technology companies that aredeveloping transformative new modalities and platforms to meaningfully improve human health.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, Canada, France
Portfolio highlights
- Remedy Plan Therapeutics — Remedy Plan is a biotechnology company developing the first drugs that halt tumor growth and disrupt the cancer stem cells that cause metastasis.
- Dispatch Bio — Dispatch Bio helps create a world where all cancer patients can be cured.
- GeneCentric Therapeutics — GeneCentric Therapeutics engages in developing and commercializing molecular diagnostic tests for oncologists and patients. The company currently has two unique platform technologies including The Lung Subtype Platform (LSP) stratifies lung cancer patients into subtypes, which are important for appropriate therapeutic selection. The firstapplication of LSP was licensed to and independently developed by Laboratory Corporation of America Holdings (“LabCorp”) and is now available through its specialty testing business, Integrated Oncology, as HistoPlusSM: Lung Cancer. Its second platform technology is the Hypoxia Signature which has the potential to identify patients that respond to anti-angiogenesis therapies.GeneCentric utilizes a unique partnership model to translate important cancer discoveries into clinically adopted diagnostics for pathologists, clinicians, and, most importantly, patients. The company was incorporated in 2011 and is based in Durham, North Carolina.
Northpond Ventures is a science-driven venture capital firm headquartered in Bethesda, Maryland. Our mission is to build a better tomorrow. Our investments are focused on life sciences, technology, and affiliated industries.
Show more
Investment focus
- Biotechnology, Health Care, Life Science
- Series A, Series B, Series C
- United States, United Kingdom, Canada
Portfolio highlights
- Vizgen — The next generation of genomics, expanding the impact of spatial context and demonstrating the potential of in situ single-cell spatial genomics.
- VieCure — The VieCure platform is an Clinical Decision Support solution in Oncology that combines the power of artificial intelligence, codified clinical rules and pathways, precision oncology, telehealth, smartphone technology, and the EMR to transform cancer care.
- Inflammatix — Inflammatix develops rapid point of care diagnostic tests by reading the immune system, and resolves major clinical health challenges.
RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. The company's team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and boardlevels. The company invests in companies with promising technologies and products.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series B, Series C, Post-IPO Equity
- United States, United Kingdom, Canada
Portfolio highlights
- Belite Bio — Belite Bio focused on first-in-class therapeutics targeting untreatable inherited orphan diseases and age-related metabolic diseases, including atrophic age-related macular degeneration, stargardt disease, and nonalcoholic steatohepatitis. They develop anti-RBP4 therapies to treat age-related metabolic diseases, including macular degeneration,liver disease, and diabetes. Their technology platform effectively reduces circulating levels of RBP4, a vitamin A transporter protein linked to the development of aging metabolic diseases, including dry age-related macular degeneration, liver disease, and diabetes.
- Reframe Systems — Robotic microfactories for building net-zero homes 2x faster, 2x cheaper with 10x lower carbon
- Alchemab Therapeutics — Alchemab Therapeutics is developing natural protective antibodies designed to keep people free of hard-to-treat diseases. They are building their transformative engine to identify novel drug targets and develop a broad pipeline of novel antibody therapeutics for hard-to-treat cancers, neurodegenerative conditions, and infectious diseases.
Learn about the approach the Novartis Venture Fund takes to investing in innovative life science companies developing biotechnology and biopharmaceutical therapeutics that address unmet patient needs.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, Switzerland, United Kingdom
Portfolio highlights
- Rhygaze — Rhygaze develops a novel gene therapy that targets cone cells to restore vision in patients suffering from diseases causing blindness.
- Granite Bio — Targeting fundamentals of Inflammation, Autoimmunity and Fibrosis. Granite Bio develops first-in-class therapeutic antibodies depleting pathogenic cells with the potential to transform inflammatory and fibrotic diseases.
- Atalanta Therapeutics — Atalanta was created to address the urgent global need for interventions to treat neurodegenerative diseases.
Third Rock Ventures invests in transformational life science companies that show high growth potential and are well-positioned to make a difference in the marketplace. Third Rock Ventures believes in the companies we start and makes significant initial investments, which are frequently supplemented by strategic collaborations, to help our firmsprogress in life-changing medicines, technologies, and diagnostics.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States
Portfolio highlights
- Trace Neuroscience — Trace Neuroscience is a biopharmaceutical company that aims to extend the promise of genetic medicine to patients with neurodegenerative illnesses.
- Candid Therapeutics — Candid Therapeutics is a biotechnology company that focuses on the treatment of a range of immunological conditions.
- Seaport Therapeutics — Seaport Therapeutics operates as a clinical stage biopharmaceutical company.
Atlas Venture is an early-stage venture capital firm that creates and invests in biotech startup companies led by promising entrepreneurs focusing on life sciences innovation. Its seed-led venture creation strategy rigorously selects and focuses investment on compelling opportunities to build scalable businesses and realize value.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, United Kingdom, Canada
Portfolio highlights
- Be Biopharma — Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.
- Renasant Bio — Renasant Bio is a biopharmaceutical company pioneering disease-modifying oral small molecule treatments.
- Vima Therapeutics — There are over 1 million people with dystonia and related movement disorders in the US and over 100,000 people with isolated dystonia.
We are deep tech venture capital.
Show more
Investment focus
- Software, Artificial Intelligence, Machine Learning
- Seed, Series A, Series B
- United States, Canada, United Kingdom
Portfolio highlights
- Halter — Halter creates GPS enabled, solar powered collars for cows. The collar hardware allows farmers to use simple tablet app software to remotely set geographic boundaries for cattle, virtual fences. Farmers use Halter's system to avoid physically herding cows, maximizing farmer time and productivity.
- Insight M — Insight M develops aerial monitoring technology for methane detection for the energy industry. It supports physical science expertise with data analytics to survey large areas, create digital maps in optical and infrared wavelengths, and scan various pipelines and acres of territory to identify major sources of gas loss.The company completed thefirst-ever basin-wide aerial survey for methane detection in its 2019 survey of the Permian Basin. Kairos Aerospace’s mission is to improve operational excellence for the oil and gas industry with cost-effective, efficient methane reductions at scale.
- Chai Discovery — Building frontier artificial intelligence to predict and reprogram the interactions between biochemical molecules.
8VC is a technology and life sciences investment firm that partners with founders to develop transformational technologies. The firm focuses on creating long-term economic and societal value through its investments across various sectors, including healthcare and logistics.
Show more
Investment focus
- Software, Health Care, Artificial Intelligence
- Series A, Seed, Series B
- United States, United Kingdom, Canada
Portfolio highlights
- Meroka — Meroka specializes in helping you seamlessly transfer ownership of your medical practice to your employees. Discover expert guidance for a smooth transition today.
- Augment — Augment is an AI tool that help the logistics company with AI assistants, emails, chats and invoicing services.
- Harbor Health — Harbor Health is a multi-specialty clinic group that provides smarter health care using technology. The company co-creates a health path that is dedicated to knowing individuals' health goals with the guidance of specialists when needed. Harbor Health was founded in 2022 and is based in Austin, Texas.
Supporting early stage Life Science startups driving patient impact. Born from our collective experience as founders, we set out to build the fund we wanted to raise from....
Show more
Investment focus
- Health Care, Biotechnology, Life Science
- Series A, Seed, Pre-Seed
- United States
Portfolio highlights
- Elegen — Skip cloning with NGS-verified, cell-free DNA up to 7 kb. Error rates as low as 1:70,000/bp. Manufactured in USA, shipped globally in 6 to 8 business days. .
- Zafrens — Zafrens specializes in developing tools and generating insights at the interface of biology, chemistry, and engineering. The company was founded in 2021 and is headquartered in San Diego, California, United States.
- Galatea Bio — Galatea Bio, a US-based biotechnology company was founder by Carlos Bustamante, Nicholas Katsanis and Alexander Ioannidis. Our mission is to drive groundbreaking discoveries in healthcare by pairing genetic diversity with cutting-edge data analytics. Our passion is fueled by a focus on populations historically underrepresented in genetics research.We achieve this by leveraging our world-class clinical network and biobank, cutting-edge algorithms, and innovative analyses to discover and validate new tests, treatments, and cures that will improve the lives of all.
DIGITAL HEALTH / AI
DIGITAL HEALTH / AI GENE / CELL THERAPIES
NASDAQ: RCKT GENE / CELL THERAPIES
NASDAQ: RCKT GENOMICS / DIAGNOSTICS GENOMICS / DIAGNOSTICS
SYNTHETIC
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Seed, Series A, Series B
- United States, United Kingdom, Brazil
Portfolio highlights
- Antheia — Transforming pharmaceutical supply chains using synthetic biology, to end drug shortages and unlock new opportunities in development and discovery
- SyntaxBio — SyntaxBio develops CRISPR/Cas9-based, genetic programming platform that converts cells into biological computers using DNA-based instructions that read like lines of code. SyntaxBio's platform can program cells without the need for consistent external intervention.
- Integrated Biosciences — Integrated Biosciences is the first company in history to be able to virtually stress cells.
Leading Global Healthcare Platform with Deep Proprietary Resources and Global Industry Coverage.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series B, Series A, Series C
- United States, China, Israel
Portfolio highlights
- CHARM Therapeutics — CHARM Therapeutics uses deep learning on 3D molecular configurations to develop molecule therapeutics to target pathogenic proteins.
- Treeline Biosciences — Treeline Biosciences is a biotech company building transformative precision medicines for patients with cancer and other serious conditions. The company was founded in 2021 and is headquartered in Stamford, CT.
- Congruence Therapeutics — ABOUT US We are a drug discovery company that is uniquely harnessing the power of protein dynamics, biophysics, machine learning and computational chemistry. Our Science Traditional drug design is limited At Congruence,
Andreessen Horowitz (a16z) is a venture capital firm in Silicon Valley, California, investing in bold founders, innovators, and entrepreneurs building the future through technology.
Show more
Investment focus
- Software, Information Technology, Internet
- Series A, Seed, Series B
- United States, United Kingdom, Brazil
Portfolio highlights
- Lead — Lead Bank is a community-minded, independent commercial bank with a national client base recognized for its imaginative approach to community banking.
- Databricks — Databricks offers a unified platform for data, analytics and AI. Build better AI with a data-centric approach. Simplify ETL, data warehousing, governance and AI on the Data Intelligence Platform.
- Allocate — Allocate is the operating system for private market alternatives investing
WE BACK HEROES using technology to solve the world's biggest problems
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Seed, Series A, Series B
- United States, Germany, Canada
Portfolio highlights
- Deepcell — Deepcell uses AI to isolate and capture cells based on morphological features for multiple research and translational applications.
- Gridware — Using remote telemetry and edge AI, Gridware wildfire prevention technology powers a grid that is smarter and more reliable than ever before.
- Aalo Atomics — Creating abundant and dependable clean energy to power humanity for generations.
Hatteras Venture Partners is a venture capital firm based in Research Triangle Park, NC, with a focus on biopharmaceuticals, medical devices, diagnostics, and related opportunities in human medicine. Founded in 2000, the firm consists of an experienced team with a broad and complementary skill set that is particularly relevant to buildingsuccessful new biomedical companies. The Hatteras Venture Partners team brings operational experience, a successful track record, and a proven ability to enhance the value of the companies in which it invests. With three funds, the firm has more than $120 million under management.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Series B, Series C
- United States, Canada
Portfolio highlights
- HistoSonics — HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels.
- Atsena Therapeutics — Atsena is a clinical-stage gene therapy company, focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness.
- GeneCentric Therapeutics — GeneCentric Therapeutics engages in developing and commercializing molecular diagnostic tests for oncologists and patients. The company currently has two unique platform technologies including The Lung Subtype Platform (LSP) stratifies lung cancer patients into subtypes, which are important for appropriate therapeutic selection. The firstapplication of LSP was licensed to and independently developed by Laboratory Corporation of America Holdings (“LabCorp”) and is now available through its specialty testing business, Integrated Oncology, as HistoPlusSM: Lung Cancer. Its second platform technology is the Hypoxia Signature which has the potential to identify patients that respond to anti-angiogenesis therapies.GeneCentric utilizes a unique partnership model to translate important cancer discoveries into clinically adopted diagnostics for pathologists, clinicians, and, most importantly, patients. The company was incorporated in 2011 and is based in Durham, North Carolina.
KdT Ventures is the standard for early-stage frontier science investing.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Seed, Series A, Series B
- United States, Israel, Germany
Portfolio highlights
- Shiprocket — Shiprocket is India's most-used eCommerce logistics and shipping software solution for the best courier services. Avail features like COD (Cash on Delivery), prepaid delivery, automated shipping, etc.
- PHNX Materials — PHNX Materials is a manufacturing company that specializes in turning waste into essential materials and reduce carbon emissions.
- Montara Therapeutics — Montara Therapeutics is a precision-medicine neuroscience biotech startup improving safety and efficacy of therapies for people with neurological diseases
Powering Breakthroughs in Life Sciences
Show more
Investment focus
- Biotechnology, Health Care, Pharmaceutical
- Series A, Series B, Series C
- United States, Canada, United Kingdom
Portfolio highlights
- āshibio — āshibio creates treatments for rare bone and connective tissue ailments, potentially preventing symptoms or slowing their course.
- Umoja Biopharma — Pioneering immunotherapy by reprogramming T cells in vivo to target cancer cells.
- Reunion Neuroscience — Reunion Neuroscience is a clinical-stage pharmaceutical company developing therapeutic solutions for underserved mental health conditions. The Company’s lead asset, RE104, is a proprietary, novel serotonergic psychedelic compound being developed as a potential fast-acting and durable antidepressant for patients suffering from postpartum depressionand other mental health conditions. Reunion is also developing the RE200 series, which includes compounds with the potential for more selective serotonin receptor activity and reduced psychoactivity for application in more chronic treatment paradigms and indications.
Sahsen Ventures is a venture capital firm making investments in for-profit and nonprofit organizations with an emphasis on technology and biotechnology. It was established in 2016 and is based in Seattle, Washington.
Show more
Investment focus
- Biotechnology, Health Care, Non Profit
- Funding Round, Series A, Seed
- United States, China, Ghana
Portfolio highlights
- Insamo — Insamo is a global biotechnology company pioneering the discovery of membrane-permeable and orally available cyclic-peptides with antibody-like binding affinity.
- Outpace Bio — Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety.It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacyand safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.
- Archon Biosciences — Archon is a biotechnology firm that creates computationally engineered proteins to unleash potent therapeutic targets beyond the grasp of current methods and improve disease management.
Artis Ventures has spent over a decade backing bold teams who take the hard path, building market-defining companies to re-shape, re-invent, and re-make industries.
Show more
Investment focus
- Health Care, Biotechnology, Software
- Series A, Series B, Seed
- United States, India, Germany
Portfolio highlights
- Network Bio — Network Bio is a clinical and molecular data library enabling precision medicine approaches for common human diseases. Its platform delivers a centralized repository for clinical and molecular data that allows researchers to identify patterns and correlations that can be used to develop new treatments and diagnostic tools.
- Outpace Bio — Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety.It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacyand safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.
- Second Front Systems — The continuous accreditation and deployment of commercial software is crucial for U.S. national security missions. With Second Front Systems' Game Warden platform, you'll be achieving exactly that.
Rev1 Ventures provides seed stage venture capital funding in Columbus, Ohio along with startup services, space, mentoring, and connections. Learn more!
Show more
Investment focus
- Software, Health Care, Information Technology
- Seed, Series A, Funding Round
- United States, Germany
Portfolio highlights
- Nichefire — Nichefire is an AI-power marketing analytics company.
- SureImpact — SureImpact is a user-friendly, social services case management software that helps you track and report outcomes, measure participant needs, and demonstrate impact to funders.
- HealthPlan Data Solutions — The HDS technology platform offers multiple solutions to help key stakeholders across the pharmacy spectrum ensure every claim adheres to the PBM contract and plan design, delivering more effective pharmacy benefit cost management.
We create breakthroughs in human health and sustainability and build bioplatform companies . Companies founded
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series B, Series C, Series A
- United States, Canada, United Kingdom
Portfolio highlights
- Etiome — Etiome is disrupting the progression of disease before it becomes debilitating and irreversible by developing and deploying Biostaged Medicines.
- Lila Sciences — Lila Sciences is a platform that uses artificial intelligence to support research in life sciences, chemical sciences, and materials sciences. It develops AI-driven tools and autonomous labs to improve research efficiency and facilitate scientific discoveries. The platform is designed to enhance various aspects of the scientific method andcontribute to advancements in technology and innovation.
- Terrana Biosciences — Terrana's innovative technological platform enables resilient agriculture in a fast changing world by providing RNA-based plant health solutions.
GV supports innovative founders moving the world forward.
Show more
Investment focus
- Software, Health Care, Biotechnology
- Series A, Series B, Seed
- United States, United Kingdom, Switzerland
Portfolio highlights
- Intent Inc — GroupUltra is a platform that allows users to program their groups and design their communities.
- Phoebe — Phoebe is an agentic search tool for tech stack data. It helps engineering teams to troubleshoot many sorts of problems much faster, from minor bugs to major incidents. Phoebe can also initiate searches proactively to help anticipate and triage new issues.
- Blue Water Autonomy — Blue Water Autonomy develops fully autonomous, unmanned ships designed from the keel up for long-endurance missions. Its vessels, about 100 feet and 100 tons, are purpose-built for open-ocean operations with modular payloads for logistics, surveillance, or munitions. The ships integrate hardware, software, and AI systems to operate independentlyover long durations. They are engineered for mass producibility, using medium-sized shipyards to keep production simpler and more cost-effective than traditional crewed ships. While initially focused on defense applications, the company also targets future use in commercial sectors such as cargo shipping, offshore energy, and other demanding maritime operations.
Longwood creates and invests in science-based companies that develop novel solutions for important medical problems
Show more
Investment focus
- Biotechnology, Therapeutics, Health Care
- Series A, Series B, Series C
- United States, United Kingdom, Italy
Portfolio highlights
- Evommune — Evommune is taking a tissue-based approach to advance insights and accelerate the development of transformative medicines in inflammatory diseases.
- Be Biopharma — Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.
- Newleos Therapeutics — Newleos Therapeutics is a biotech startup dedicated to producing safer and more effective neuroscience medicines.
Cormorant Asset Management is an employee-owned hedge fund sponsor that provides its services to pooled investment vehicles. The firm also focuses on both public and private market innovative companies in the biotechnology and life sciences marketplace.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series B, Series A, Series C
- United States, China, Switzerland
Portfolio highlights
- Numab — Numab Therapeutics AG
- Neurona Therapeutics — Neurona Therapeutics is a pre-clinical stage biotechnology company that was founded by four neuroscientists and stem cell pioneers at The University of California, San Francisco. They are focused on the discovery and development of cell-based therapies to treat intractable neurological disease. Its initial aim is to generate therapeuticcompositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. Based on nearly two decades of research, they believe that particular subpopulations of neurons have the unique ability to integrate and repair dysregulated neural circuits. Its talented team of scientists, scientific advisors, and board directors is working to accelerate breakthrough treatments for patients with significant unmet medical needs.
- Edgewise Therapeutics — See how we bring our unique expertise and singular focus on muscle science to develop novel therapeutics for serious skeletal and cardiac muscle diseases.
Playground Global is an early-stage venture capital firm backing technical and scientific founders with deep engineering expertise, a collaborative environment, and a first-hand understanding of the intricacies of deep tech. Established in 2015 and headquartered in Palo Alto, CA, Playground’s mission is to transform ambitious ideas into impactfulbusinesses that benefit humanity and the planet. We invest in areas that span across next gen compute automation, energy transition and engineered biology. Playground has been an early – and frequently first investor – in companies that include PsiQuantum, Relativity Space, Ultima Genomics, MosaicML (acq. by Databricks), d-Matrix, and Strand Therapeutics.
Show more
Investment focus
- Software, Robotics, Biotechnology
- Series A, Seed, Series B
- United States, Canada, France
Portfolio highlights
- xLight — xLight to commercialize particle accelerator driven Free Electron Lasers (FEL) for critical US economic and national security applications.
- Aerones — Robotic wind turbine service company offering maintenance, inspection and repairs worldwide. Reduce downtime and improve the efficiency of your wind park
- Snowcap Compute — Snowcap Compute develops advanced artificial intelligence computing chips that leverage superconducting technology for faster processing and greater energy efficiency.
ATP, a global leader in life sciences venture capital, is developing the next generation of transformative biotechnology companies. ATP creates science-based companies starting with assets at various stages: from working with scientists on pre-IP ideas, to spinouts from existing company pipelines. The firm provides flexible capital, strategicinsight, and operational resources to build sustainable, research-driven enterprises. ATP invests in its portfolio companies from seed stage through IPO and beyond and supports their management teams in strategic transactions and synergistic business combinations.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Seed
- United States, Canada, United Kingdom
Portfolio highlights
- Ascidian Therapeutics — Ascidian Therapeutics is a biotechnology company developing exon-editing RNA therapeutics to target the underlying causes of disease.
- Red Queen Therapeutics — Staying ahead of viral threats with new innovations in antiviral therapy
- Deep Apple Therapeutics — Deep Apple Therapeutics is discovering new small-molecule therapeutics with unprecedented speed and exceptional acumen.
Venture investing in Food, Health, and AgTech. A generational investment thesis. Food is Health is longevity
Show more
Investment focus
- Biotechnology, Health Care, Software
- Seed, Series A, Funding Round
- United States, Australia, New Zealand
Portfolio highlights
- Geltor — The leader in biotech-powered proteins for beauty and wellness, including vegan collagen, elastin, and more, purposefully biodesigned for performance.
- Mercy BioAnalytics — We are making early stage cancer 100,000x easier to find using extracellular vesicles found in blood, specific to their parent cells.
- Growers Edge — Growers Edge leverages data science to build grower-relevant risk management solutions to meet ever-changing agricultural demands.
Foundational partners to ambitious founders at every stage of company-building.
Show more
Investment focus
- Software, Health Care, Biotechnology
- Series A, Series B, Series C
- United States, India, Canada
Portfolio highlights
- Aurelian — Aurelian is an AI platform designed to automate routes, triage, and resolve non-emergency police calls.
- Mojo Vision — Mojo Vision is a developer of augmented reality products and platforms intended to invent the future of computing. The company has developed a smart contact lens with a built-in display that gives timely information without interrupting the focus and delivers immediate, powerful, and relevant information without the intrusions of today'smobile devices, enabling users to connect with others at a glance, anytime, anywhere handsfree.Mojo Vision was founded in 2015 and headquartered in Saratoga, California.
- Strive Health — Strive Health is a built-for-purpose company working with innovative payors and providers to transform kidney care. Strive Health significantly improves patient outcomes and experience with a high-touch, technology-enabled clinical model that cares for chronic kidney disease patients across their entire healthcare journey, from primary care-levelengagement through dialysis. Strive was launched out of Oxeon’s Venture Studio and is backed by New Enterprise Associates, Town Hall Ventures, Echo Health Ventures, and Ascension Ventures.
Pear VC partners with entrepreneurs from day zero to build category-defining companies.
Show more
Investment focus
- Software, Artificial Intelligence, Health Care
- Seed, Series A, Pre-Seed
- United States, Brazil, Colombia
Portfolio highlights
- Dealops — Dealops is the first deal pricing platform that brings commercial strategy and sales enablement into quoting. Sales moves fast, Finance stays in control, and every deal drives margin and growth.
- TrueMeter — EcoTrove is your energy concierge for cheaper, greener and more predictable power bills.
- August — Custom agent-driven workflows built for your practice
The Column Group (TCG) is a venture ecosystem dedicated to fueling scientific innovation in the life sciences industry.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States
Portfolio highlights
- A2 Biotherapeutics — A2 is dedicated to advancing cancer treatment through pioneering cell therapy. Our T cells target solid tumors with precision, transforming the future of medicine.
- Eikon Therapeutics — Eikon Therapeutics is a drug discovery and development company that leverages super-resolution microscopy as well as the latest advances in biology, chemistry, engineering, and automation toward the goal of discovering and inventing innovative therapies that will improve and extend life.
- Neurona Therapeutics — Neurona Therapeutics is a pre-clinical stage biotechnology company that was founded by four neuroscientists and stem cell pioneers at The University of California, San Francisco. They are focused on the discovery and development of cell-based therapies to treat intractable neurological disease. Its initial aim is to generate therapeuticcompositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. Based on nearly two decades of research, they believe that particular subpopulations of neurons have the unique ability to integrate and repair dysregulated neural circuits. Its talented team of scientists, scientific advisors, and board directors is working to accelerate breakthrough treatments for patients with significant unmet medical needs.
The firm is a 25-year-old global investment firm focused on healthcare with approximately $5.8 billion in AUM, which we have invested in over 290 public and private companies worldwide. Headquartered in Palo Alto, California, with offices in Asia. Our team consists of 50 multi-disciplinary professionals, including, physicians, scientists,entrepreneurs, operating executives, and industry experts.
The firm operates as a multi-fund investment platform, covering growth equity, private
equity including buyout, venture capital, and public equity. Vivo invests broadly in healthcare across all fund strategies, including biotechnology, pharmaceuticals, medical devices, and healthcare services, with a focus on the largest healthcare markets.
Show more
Investment focus
- Biotechnology, Health Care, Pharmaceutical
- Series B, Series C, Post-IPO Equity
- United States, China, United Kingdom
Portfolio highlights
- CAMP4 Therapeutics — CAMP4 is focused on addressing the fundamental cause of disease by controlling the output of genes central to disease. By taking advantage of the gene circuitry code, CAMP4 is able to control gene production through signaling pathways the cell is already utilizing to regulate gene expression. Their predictions enables CAMP4 to have a rapid start todisease treatment, significantly reducing the time and risk to bring new medicines to patients.
- Trevi Therapeutics — Trevi Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF), andlevodopa-induced dyskinesia (LID) in patients with Parkinson’s disease. These conditions share common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Trevi is currently conducting a Phase 2b/3 clinical trial of nalbuphine ER, referred to as the PRISM trial, in patients with severe pruritus associated with prurigo nodularis.
- Chentai New Materials — Chentai New Materials integrates the R&D, design, manufacturing, and sales of high-performance composite ceramics. It Specializes in the innovation and creation of medical high-performance ceramic products.
SR One Capital Management is a leading trans-Atlantic biotech venture capital firm that partners with top entrepreneurs, scientists and investment partners to seek to build elite biotechnology companies. Our mission is to translate ground-breaking technologies into next generation medicines to benef
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, United Kingdom, Canada
Portfolio highlights
- Fore Biotherapeutics — We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics.
- Draig Therapeutics — Draig Therapeutics is a clinical-stage biopharmaceutical startup dedicated to creating next-generation treatments for serious neuropsychiatric illnesses.
- ORIC Pharmaceuticals — ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s lead product candidate,ORIC-101, is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeuticsacross a variety of solid tumors. ORIC’s second product candidate, ORIC-533, is an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens. Beyond these two product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC’s scientific founders, Charles Sawyers, MD, and Scott Lowe, PhD, have long records of discovering novel targets in cancer that have led to innovative treatments.
Lux Capital manages over $5 billion in assets focused on founding, seed, early-stage, and growth investments at the intersection of technology and the sciences. Lux takes an active role in helping entrepreneurs build successful businesses in high-growth sectors. Its investment team has built over 20 companies from scratch. Lux's investmentstrategy ensures portfolio companies are better connected, have a deeper insight, and command industry leadership faster than their competitors.
Show more
Investment focus
- Software, Health Care, Artificial Intelligence
- Series A, Seed, Series B
- United States, United Kingdom, Canada
Portfolio highlights
- Armada — The Armada Platform is a whole new way to succeed at the Edge with Starlink connectivity, mobile data centers & AI. Schedule a demo today.
- Hadrian — We are building the planet's most efficient factory to accelerate a democratic, abundant, spacefaring future.
- Basic Capital — Stand out with the only 401(k) that gives your employees more capital to invest and build wealth.
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Series B, Series C
- United States, Switzerland, Canada
Portfolio highlights
- Granite Bio — Targeting fundamentals of Inflammation, Autoimmunity and Fibrosis. Granite Bio develops first-in-class therapeutic antibodies depleting pathogenic cells with the potential to transform inflammatory and fibrotic diseases.
- Helicore Biopharma — Helicore Biopharma is at the forefront of developing cutting-edge treatments for obesity and related disorders.
- Kriya Therapeutics — Kriya is a biopharmaceutical company developing gene therapy to address common diseases that impact millions of people worldwide. Learn more.
5AM Ventures is a venture capital firm that offers seed- and early-stage investments to its clients. The company’s client portfolio consists of firms in the biopharmaceutical, life sciences, medical technology, and research instrument industries.
5AM Ventures was founded in 2002 by John Diekman and Andrew Schwab and is based in California.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, Switzerland, United Kingdom
Portfolio highlights
- Fellow Health — Test sperm privately from home and get a doctor-reviewed male fertility report containing detailed semen analysis results.
- Renasant Bio — Renasant Bio is a biopharmaceutical company pioneering disease-modifying oral small molecule treatments.
- CAMP4 Therapeutics — CAMP4 is focused on addressing the fundamental cause of disease by controlling the output of genes central to disease. By taking advantage of the gene circuitry code, CAMP4 is able to control gene production through signaling pathways the cell is already utilizing to regulate gene expression. Their predictions enables CAMP4 to have a rapid start todisease treatment, significantly reducing the time and risk to bring new medicines to patients.
We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, Switzerland, United Kingdom
Portfolio highlights
- Windward Bio — Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with advanced immunological diseases.
- Alleviant Medical — Interventional therapy for congestive heart failure
- Callio Therapeutics — Callio Therapeutics focuses on developing next-generation, multi-payload antibody-drug conjugates to maximize therapeutic benefits.
Breakout Ventures is a new, early stage fund that backs bold scientist entrepreneurs working at the intersections of technology, biology, materials, and energy.
Show more
Investment focus
- Biotechnology, Life Science, Therapeutics
- Seed, Series B, Series A
- United States
Portfolio highlights
- CytoVale — Cyotvale offers IntelliSep, an FDA-cleared early sepsis detection test powered by the Cytovale System medical device.
- Passkey — Passkey Therapeutics is pioneering a new class of medicines, Synergistic Multifunctional Therapeutics (SMThs). It is designed to address complex diseases by targeting rare combinations of proteins that work together.
- Copernic Catalysts — Mantel is developing the material solution to carbon capture
O'Reilly AlphaTech Ventures (OATV) is in the business of funding disruptors, innovators, and hackers of the status quo. From open source to the early days of the web and its recent resurgence, O'Reilly Media has played a key role as trend spotter and advocate for putting world-changing technologies on the map. OATV effort is to bring thelegacy, resources, and relationships of O'Reilly to each investment they make.
Show more
Investment focus
- Software, E-Commerce, Analytics
- Series A, Seed, Series B
- United States, United Kingdom, Canada
Portfolio highlights
- Pachama — Harnessing AI to drive carbon capture and protect global forests
- Paintbrush — Paintbrush provides access to funding for idea-stage founders who are too early for other options.
- Impart Security — Real-time API Security spanning discovery, monitoring, and enforcement.
Mission BioCapital is a life science venture capital firm that invests in early-stage companies. The company leadership team has a long history together, investing in and launching dozens of early-stage life science companies. They are located in regions with a rich concentration of research, discovery, and venture capital investment, and they areknown by leaders of portfolio companies for the expertise and deep support they provide.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Funding Round, Series B
- United States, Germany, Switzerland
Portfolio highlights
- D2B3 — The future of treating brain diseases.
- Alessa Therapeutics — Alessa Therapeutics is a pre-clinical stage company that develops localized treatments for solid organ disease.
- SiteOne Therapeutics — SiteOne develops selective inhibitors of sodium channels as non-opioid treatments to address acute and chronic pain
Investing in early-stage companies solving the biggest science and engineering challenges since 2014.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Seed, Series B
- United States, Austria, Switzerland
Portfolio highlights
- Magnefy — Optimize your transformer monitoring with our innovative predictive maintenance solutions using AI & advanced magnetic sensor technology.
- Montara Therapeutics — Montara Therapeutics is a precision-medicine neuroscience biotech startup improving safety and efficacy of therapies for people with neurological diseases
- Esper Satellite Imagery — Esper is building and launching the world's most versatile satellite imagery network for mineral exploration, agronomy, and national security. Order imagery now.
Engineering solutions to complex problems in health through venture investment and company creation.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Seed
- United States, United Kingdom, China
Portfolio highlights
- ASTRA Therapeutics — Astra - Therapeutics
- Gallant Therapeutics — Gallant Therapeutics is an animal health biotechnology company developing allogeneic, "off-the-shelf" stem cell therapies from their stem cell platform. Gallant is also the leading provider of non-invasive stem cell banking during the spay or neuter process, opening the door to novel regenerative medical treatments formerly unavailablefor non-human family members. Clinical studies demonstrate stem cell therapies help pets with a multitude of ailments, including osteoarthritis, atopic dermatitis, chronic kidney disease, and chronic stomatitis, among others. Gallant's first product helps to save cats that would die of chronic gingivostomatitis, with a robust pipeline in development for companion animals.
- Positive Development — At Positive Development we empower children with autism and their families through the developmental model of autism therapy. Our developmental model respects the individuality of every child on the autism spectrum with treatment based on their strengths and how they process the world around them.
At Connecticut Innovations, we see venture capital the way you see your business. Like no one else. We invest in innovative biotech, IT, and other industries.
Show more
Investment focus
- Health Care, Biotechnology, Software
- Seed, Series A, Funding Round
- United States, Israel, Canada
Portfolio highlights
- Normunity — We create medicines that free normal immunity to defeat cancer using proprietary platforms that uncover novel immuno-oncology mechanisms.
- VeraDermics — VeraDermics Inc. is a dermatology pharmaceutical start-up, makers of WartPatch
- PHȲND — PHȲND is a subscription-free cloud gaming platform that offers a way to discover, play, and socialize across a wide variety of games.
Investing in the deep science and technology that can propel humanity towards a radically better future.
Show more
Investment focus
- Biotechnology, Artificial Intelligence, Software
- Series A, Series B, Seed
- United States, United Kingdom, Canada
Portfolio highlights
- Xampla — Xampla's natural plant polymer technology is the innovative technology powering materials to change the world with plastic-free replacements and more.
- Harrison.ai — And a thirst for knowledge meets a passion for a better world.A world where people are cared for by people, medical data analysis is done at scale,
- Owlstone Medical — Owlstone Medical has developed a breathalyzer for disease. With a focus on non-invasive diagnostics for cancer, inflammatory disease, and infectious disease, the company aims to save 100,000 lives and $1.5B in healthcare costs.The company’s Breath Biopsy® platform has introduced a new diagnostic modality making it possible to discover novelnon-invasive biomarkers in breath using a platform with the potential to transition to point-of-care. The award-winning ReCIVA Breath Sampler ensures a reliable collection of breath samples. The volatile organic compounds (VOCs) present in the breath are analyzed using proven microchip chemical sensor technology (FAIMS) to detect biomarkers of disease.The Breath Biopsy platform can be used in clinical diagnostics and precision medicine with applications in cancer and a wide range of other medical conditions. Highly sensitive and selective, these tests allow for early diagnosis when treatments are more effective and more lives can be saved.Owlstone Medical is currently developing tests for lung and colorectal cancer, two of the most common cancer killers worldwide, and for asthma stratification by the therapeutic response. The company also Breath Biopsy products and services to academic, clinical, and pharma partners who want to develop breath-based diagnostics for their own applications.
We are a multi-stage investment firm, investing in companies that leverage biology and big data to transform healthcare.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series B, Series C, Series A
- United States, United Kingdom, Australia
Portfolio highlights
- RayThera — RayThera specializes in developing breakthrough small molecule therapies for critical unmet needs in immunology. Backed by decades of drug discovery expertise, we accelerate the development process while maintaining rigorous standards.
- Eikon Therapeutics — Eikon Therapeutics is a drug discovery and development company that leverages super-resolution microscopy as well as the latest advances in biology, chemistry, engineering, and automation toward the goal of discovering and inventing innovative therapies that will improve and extend life.
- Latigo Biotherapeutics — Operator of a drug discovery company intended to develop novel, non-opioid therapies for chronic pain. The company utilizes unique, translated insights to provide a differentiated approach to targeting therapeutics across the blood-nerve barrier, enabling patients to get access to a pain management therapy that does not create addiction, dependenceor tolerability.
We invest in companies that are advancing the field of genomics and pioneering new applications in healthcare, agriculture, environmental science, and personal
Show more
Investment focus
- Biotechnology, Health Care, Life Science
- Series A, Series B, Series C
- United States, United Kingdom, France
Portfolio highlights
- Arima Genomics — Use the most advanced Hi-C technology to power your discoveries with unparalleled access to the sequence + structure of any genome.
- Infinity Bio — Learn how Infinity Bio's antibody profiling services can detail the reactome in your samples.
- Attovia Therapeutics — Attovia Therapeutics is a biotherapeutics pipeline developer focused on immune-mediated illness and oncology. The company uses the nanobody platform to create tiny format binders with low picomolar affinity, increased selectivity, quicker internalization, and rapid tissue penetration, thereby assisting cancer patients in being treated.
F-Prime Capital is a global venture capital firm investing in healthcare and technology, with a heritage that spans four decades.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Series B, Series C
- United States, United Kingdom, China
Portfolio highlights
- Dinari — Discover Equity Boundless - Simplify everything from equity management and options grant to payroll so that you no longer have to worry about compliance, taxes, or vesting schedules no matter where your employees are.
- Toku — Toku helps companies to automate collections and facilitate payment processes. Toku enables companies to optimize the collection of recurring payments.
- Galatea Bio — Galatea Bio, a US-based biotechnology company was founder by Carlos Bustamante, Nicholas Katsanis and Alexander Ioannidis. Our mission is to drive groundbreaking discoveries in healthcare by pairing genetic diversity with cutting-edge data analytics. Our passion is fueled by a focus on populations historically underrepresented in genetics research.We achieve this by leveraging our world-class clinical network and biobank, cutting-edge algorithms, and innovative analyses to discover and validate new tests, treatments, and cures that will improve the lives of all.
We are the corporate venture fund of Roche, a global leader in bringing medicines and in vitro diagnostics to the benefit of patients.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series B, Series A, Series C
- United States, United Kingdom, Spain
Portfolio highlights
- DiogenX — Welcome to DiogenX. Explore our pioneering research and innovative therapies aimed at transforming diabetes treatment
- Mironid — Google Analytics is a web analysis service provided by Google. Google utilizes the data collected to track and examine the use of www.mironid.com, to prepare reports on its activities and share them with other Google services. Google may use the data collected to contextualize and personalize the ads of its own advertising network.
- MISSION Therapeutics — Deubiquitylating enzymes: multiple drug opportunities across therapeutic areas
The JDRF T1D Fund (www.t1dfund.org) is a venture philanthropy fund exclusively devoted to finding and funding the best early-stage T1D commercial opportunities to accelerate the delivery of treatments, preventions, and cures to patients. It was created to solve a critical funding gap in the T1D drug and device development pipeline. Throughpartnerships with private capital, including venture capital, pharma and foundations, the T1D Fund anticipates that it will be able to attract substantially more private investment to the T1D field than occurs today. The T1D Fund will initially focus on artificial pancreas systems, metabolic control, beta cell replacement, prevention, and beta cell restoration therapies, with an exclusive priority on the best commercial opportunities. The T1D Fund will reinvest any realized gains into new investments to further its mission.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Funding Round, Series B
- United States, France, Italy
Portfolio highlights
- vTv Therapeutics — vTv Therapeutics, a pharmaceutical company, focuses on the discovery and development of human therapeutics to fill unmet medical needs. Its mission is to utilize its innovative technology to rapidly translate the functional modulation of human proteins into safe and effective medicines.vTv Therapeutics has a pipeline of small molecule clinicaland pre-clinical drug candidates for the treatment of a wide range of human diseases including central nervous system disorders, metabolic disorders, inflammation, and cancer. The company has built its product candidate portfolio through internal discovery and is advancing its product candidates through in-house research and development efforts. The quality and breadth of vTv's product candidate pipeline, platform technology, scientific team, and strategic collaborations have enabled it to become a fully integrated pharmaceutical company.The company's commitment to drug discovery is reflected in its medical solutions and the many exciting potential new treatment options in its pipeline. The company's major R&D activities have focused on central nervous system disorders, metabolic disorders, inflammation and oncology.vTv Therapeutics is advancing several proprietary drug candidates. The company's lead candidate, azeliragon (aka TTP488), is a novel, orally bioavailable small molecule compound that is being developed for the treatment of Alzheimer's disease. In Phase 2 clinical trial in patients with mild to moderate Alzheimer's disease, azeliragon showed a statistically significant difference of more than 3 points in ADAS-cog at 18 months compared to placebo.Azeliragon has been granted Fast Track Designation and agreement on its Phase 3 protocol has been reached with FDA via a Special Protocol Assessment (SPA). The Phase 3 study in patients with mild Alzheimer's disease was initiated in April 2015 with a clear path forward to registration with the aim to demonstrate disease modification.vTv Therapeutics is also prosecuting the clinical development of TTP399, a novel functionally liver-selective Glucokinase Activator ("GKA") for the treatment of type 2 diabetes. In a Phase 2a study, TTP399 normalized patients' HbA1c without inducing hypoglycemia, after only six weeks of treatment. A six-month Phase 2 study is ongoing.
- Eledon Pharmaceuticals — Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people undergoing organ or cellular transplantation, and for people with autoimmune and neurodegenerative disease.
- Cour Pharmaceuticals Development — Reprogramming the immune system. Restoring lives.At COUR, we develop targeted therapies that incite calm within the immune system and help restore the healt ...
First Round is a seed-stage venture firm focused on building a vibrant community of technology entrepreneurs and companies.
Show more
Investment focus
- Software, Information Technology, E-Commerce
- Seed, Series A, Series B
- United States, Canada, India
Portfolio highlights
- Andrenam — Andrenam is building an AI-powered, distributed maritime sensing network for persistent autonomous awareness from surface to seabed.
- Solidroad — Increase CSAT without increasing cost with the AI QA & training platform that reviews 100% of your customer conversations. Generate individualized training simulations for human reps and refinement recommendations for AI agents.
- arketa — Online and in-person classes, video on-demand, courses and website hosting - all in one platform with arketa.
Investors by industry
Google
Marketplace
Hardware
Energy
Proptech
Health Care
Biotech
Artificial intelligence
Climate
Consumer
Community
Impact
Gaming
FinTech
EdTech
Sustainability
Venture Capital
Big Data
Web3
B2B
Financial Services
Finance
Infrastructure
Education
Photography
Payments
Food and Beverage
Video Games
Organic Food
Retail
Beauty
Publishing
Clean Energy
Real Estate
Manufacturing
Art
Music
Android
Internet
Enterprise Software
eSports
Franchise
Sports
Construction
Digital Media
Email
Medical
Social Network
Wellness
Social Media
Mobile
Legal
Local
Recruiting
Cannabis
Platforms
Fitness
Travel
Mobile Advertising
Biotechnology
Hospitality
Social
Automotive
Crowdfunding
Wine And Spirits
Medical Device
CleanTech
Transportation
Mobile Apps
InsurTech
Enterprise
LGBT
Fashion
Oil and Gas
Life Science
Theatre
Film
Non Profit
Renewable Energy
SaaS
Sporting Goods
Restaurants
Social Impact
Software
Celebrity
Cryptocurrency
Machine Learning
Agriculture (agtech)
Media (entertainment)
Facebook
Blockchain
Investors by country
United Kingdom
Canada
South Korea
Ireland
United States
New Zealand
India
Germany
Australia
Armenia
South Africa
Spain
Japan
Africa
China
Sri Lanka
Singapore
Qatar
Asia
Indonesia
Vietnam
Oceania
LATAM
Middle East
Europe
Saudi Arabia
Brazil
Bulgaria
Belize
Bahrain
Croatia
Georgia
Belarus
Hungary
France
Ghana
Ethiopia
Gibraltar
Chile
Egypt
Finland
Costa Rica
Greece
Barbados
Belgium
Estonia
Bermuda
Czech Republic
Denmark
Algeria
Hong Kong
Ecuador
Faroe Islands
Liechtenstein
Liberia
Lebanon
Mauritius
Peru
Norway
Sierra Leone
El Salvador
Uganda
Venezuela
Sweden
Israel
Slovenia
Poland
Uruguay
Ukraine
Malaysia
Tajikistan
Puerto Rico
Portugal
Tunisia
Taiwan
Tanzania
Turkey
San Marino
Senegal
Togo
Uzbekistan
Serbia
Russian Federation
Zambia
Rwanda
Zimbabwe
Thailand
Dominican Republic
Mexico
Nicaragua
Azerbaijan
Jersey
Iceland
Nigeria
Panama
Bahamas
Namibia
Iraq
United Arab Emirates
Jamaica
Morocco
Honduras
Mali
Lithuania
Isle of Man
Bolivia
Luxembourg
Italy
Philippines
Pakistan
Albania
Kuwait
Malta
Myanmar
Kenya
Grenada
Jordan
Romania
Bangladesh
Argentina
Kazakhstan
Cayman Islands
Cambodia
Oman
Latvia
Cyprus
Austria
Switzerland
Cameroon
Colombia
Guatemala
Marshall Islands
Seychelles
Investors in United States by industry
Enterprise
FinTech
Health Care
Biotech
Consumer
Climate
EdTech
Marketplace
SaaS
Artificial intelligence
Community
Hardware
Gaming
Restaurants
Venture Capital
Film
Retail
B2B
LGBT
Video Games
Financial Services
Education
Oil and Gas
Proptech
Cryptocurrency
Payments
Food and Beverage
Wine And Spirits
Organic Food
Crowdfunding
Medical
Internet
Wellness
Email
Social Media
Social Network
Manufacturing
Celebrity
Art
Theatre
Blockchain
Android
Franchise
Construction
Google
Legal
Software
Local
Sports
eSports
Fitness
Hospitality
CleanTech
Automotive
InsurTech
Travel
Biotechnology
Cannabis
Mobile Advertising
Beauty
Real Estate
Fashion
Social
Web3
Life Science
Photography
Sporting Goods
Publishing
Renewable Energy
Mobile
Mobile Apps
Infrastructure
Social Impact
Recruiting
Sustainability
Non Profit
Clean Energy
Platforms
Finance
Impact
Music
Digital Media
Transportation
Facebook
Media (entertainment)
Machine Learning
Enterprise Software
Big Data
Medical Device
Agriculture (agtech)
Energy